PubMed · 7746074
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J E Mangino, S A Moser, K B Waites. 1995-05-20. When to use fluconazole.. https://doi.org/10.1016/s0140-6736(95)90951-6
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Comparison [+/- 1 dilution between minimum inhibitory concentrations (MICs)] of fluconazole and flucytosine Etest MICs of 10 candidate quality control yeast isolates and 78 clinical isolates demonstrated good agreement (> or = 90%) with the reference method (National Committee for Clinical Laboratory Standards document M27-P). This study suggests that the Etest is a promising alternative method for antifungal susceptibility testing in the clinical laboratory, but that further evaluations are needed.
The involvement of central nervous system in paracoccidiodomycosis has rarely been described, with an incidence rate varying from 9.99% to 27.27%. There are two basic forms of clinical presentation: meningeal and tumor-like (abscesses, granulomas, nodules, and cysts). The Paracoccidioides brasiliensis is preferentially described in cerebral hemispheres, cerebellum, medulla oblonga and meninges, and exceptionally in the spinal cord. The authors present a case of paracoccidioidomycosis which diagnosis was achieved by microscopic examination of material from oral lesions and specific serology. The patient presented clinical signs of spinal cord involvement confirmed by lesions found in magnetic resonance imaging. They emphasize the inedit therapeutic response to a new antifungal agent (fluconazole) used for the first time in this kind of clinical manifestation, and the excellent prognosis when diagnosis is promptly made.
Explore the source record for details and available documents.